Sphera Funds Management Ltd. Gracell Biotechnologies Inc. Transaction History

Sphera Funds Management Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.43 - $10.04 $2.5 Million - $10.3 Million	-1,028,561 Reduced 67.16%	502,936 $5.05 Million
Q3 2023 Nov 14, 2023	BUY	$2.83 - $4.9 $857,014 - $1.48 Million	302,832 Added 24.65%	1,531,497 $4.41 Million
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $1.64 Million - $6.87 Million	-1,131,915 Reduced 47.95%	1,228,665 $4.68 Million
Q1 2023 May 15, 2023	BUY	$1.8 - $2.5 $4.25 Million - $5.9 Million	2,360,580 New	2,360,580 $4.39 Million
Q3 2021 Nov 15, 2021	SELL	$9.91 - $14.84 $2.32 Million - $3.47 Million	-233,850 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$9.75 - $18.42 $207,187 - $391,425	21,250 Added 10.0%	233,850 $3.04 Million
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $3.13 Million - $6.5 Million	212,600 New	212,600 $3.27 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.